QS Research · Michael Burry's Scion Capital analyst template · 2006
Cencora, Inc. (COR)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $356.94 (close 2026-11-16); latest close $339.09 (2026-11-20), -5.0% since the report; figures re-marked at the latest close
Conclusion: WATCH
Conviction low · base case +47% · downside -18% · upside +57%
The market pays 0.23x TTM EV/Sales for Cencora, below the 0.31x peer median, while the business earns 18.6% ROIC against a 5.5% WACC and a 6.0% FCF yield; that spread is what the market is missing. The call is WATCH with low conviction: the 0.31x anchor rests on only three peers, and a 4.0% gross margin, about 66% top-10 customer concentration, $8.91B net debt and $1.09B TTM impairments leave little room for error. Downside is -21.8% to $279.18 on -5.0% sales at a compressed EV/Sales of 0.2x (today 0.23x). Base is +39.3% to $497.33 on EV/Sales at 0.31x, the peer median EV/Sales (3 peers in the comps table: MCK 0.31x, CAH 0.27x, IQV 3.31x). Upside is +49.0% to $531.84 on a re-rating to 0.31x on the cited dated catalyst.
Key numbers
- Share price: $339.09
- Market cap: $64.71B
- Latest financial period: TTM to Jun 30, 2026
- Revenue (TTM): $332.77B
- EV / EBITDA (TTM): 18.1x
- P/E (TTM): 24.7x
- FCF yield: 6.3%
- Price / book: 21.21x
- Earnings-quality flags (TTM): Impairments -$1.09B (41% of net income)
- P/E, adjusted (TTM): 17.5x
- P/E, operating (tax-normalized) (TTM): 29.1x
- EV / FCF (TTM): 18.2x
- Revenue growth (latest fiscal year): +9.3%
- ROIC (TTM): 18.6%
- WACC: 5.5%
- Economic profit spread: +13.2 pts
The 15 boxes
- ✓ 1. Long-form business notes
Cencora (formerly AmerisourceBergen) is a high-volume pharmaceutical sourcing and distribution business: FY2025 revenue was $321.33B against $11.48B of gross profit, i.e. low-margin distribution volume plus fee-based services to providers and manufacturers. Over the six fiscal years in the data, revenue rose from $189.89B (FY2020) to $321.33B (FY2025) and gross profit from $5.19B to $11.48B, while FY2020 was a loss year (operating income -$5.14B, net income -$3.41B). The TTM to 2026-06-30 shows $332.77B revenue, $3.04B operating income, $2.62B net income and $4.82B operating cash flow, with pre-tax income ($3.61B) running above operating income, so part of the TTM bottom line is non-operating and not broken out in these sources. Between the FY2020 and FY2025 Item 1 descriptions the business purpose is essentially unchanged; the name changed to Cencora and the services language expanded.
- ✓ 2. Competitive advantage
Cencora's advantage is distribution scale and cost, not brand or pricing power: management believes it has one of the lowest operating cost structures among pharmaceutical distributors, but FY2025 gross profit was $11.48B on $321.33B of revenue and operating income was $2.63B. Operating income was roughly flat at $2.18B-$2.63B in FY2021-FY2025, and FY2020 had a $5.14B operating loss. Competition is intense from McKesson, Cardinal, UPS Logistics and direct/alternative channels, while top-10 customers were about 66% of FY2025 revenue.
- ✓ 3. 10-Q takeaways
The latest 10-Q in the source set is Q3 FY2026 (quarter ended June 30, 2026): revenue rose 5.1% to $84.8B, gross margin was 4.26% (+66 bps), and operating income was $1.1B (+29.1%), with the quarter's opioid-litigation credit and nine-month OneOncology remeasurement gain kept outside operating comparisons. Nine-month operating cash flow improved to $1.7B, Q3 buybacks were $1B, and FY2026 adjusted EPS guidance was raised to $17.75-$17.95. The 10-Q risk-factor section points back to the FY2025 10-K; the source's computed risk-factor diff is for that 10-K, not the 10-Q.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.